| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
BET bromodomain proteins. Hexamethylene bisacetamide inhibits BET bromodomain proteins. As a BET inhibitor, it displaces BET proteins from chromatin, leading to transcriptional changes. It also inhibits activation of NF-κB, Akt, and ERK/MAPK pathways. The compound modulates signaling pathways including Notch1, Bcl-2, and p53.
|
|---|---|
| ln Vitro |
HMBA induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines. It displaces BET proteins from chromatin, causing massive transcriptional changes. It triggers cell-cycle arrest and apoptosis in Myc-induced B-cell lymphoma cells. The compound inhibits activation of NF-κB, Akt, and ERK/MAPK pathways.
|
| ln Vivo |
HMBA induces tumor cell differentiation and inhibits cell proliferation, showing antitumor activity. It can cross the blood-brain barrier. The compound has been studied for its potential in treating hematologic cancers and solid tumors. It exhibits anticancer activity and is used to induce cellular differentiation and apoptosis in cancer cells.
|
| Enzyme Assay |
HMBA is evaluated in cell-free assays for BET bromodomain binding. The compound is incubated with BET bromodomain proteins, and binding affinity is measured using techniques such as surface plasmon resonance (SPR) or fluorescence polarization. The compound's ability to displace BET proteins from chromatin can be assessed using biochemical assays.
|
| Cell Assay |
HMBA is assessed in cell-based assays using cancer cell lines, including Myc-induced B-cell lymphoma cells. Cells are treated with HMBA, and cell differentiation, cell cycle arrest, and apoptosis are measured. The compound induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines. It displaces BET proteins from chromatin and causes transcriptional changes.
|
| Animal Protocol |
HMBA is administered in animal models to evaluate its antitumor efficacy. It has been studied in models of hematologic cancers and solid tumors. Efficacy is assessed by measuring tumor growth inhibition, differentiation, and apoptosis. The compound can cross the blood-brain barrier, suggesting potential for treating brain tumors.
|
| ADME/Pharmacokinetics |
HMBA has a molecular weight of 200.28 and a molecular formula of C10H20N2O2. It has a CAS number of 3073-59-4. The compound is soluble in DMSO and should be stored at -20°C. It is a hybrid polar-planar compound with potential antineoplastic activity.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for HMBA. The compound is for research use only and is not intended for human therapeutic use. It has been studied for its potential antineoplastic activity and ability to induce differentiation and apoptosis in cancer cells. Specific toxicity studies have not been well-characterized in the available literature.
|
| Additional Infomation |
N-(6-acetaminohexyl)acetamide belongs to the acetamide class of compounds. Hexamethylene diacetamide is a polar planar hybrid compound with potential antitumor activity, capable of inducing terminal differentiation in various tumor cell lines, inhibiting cell growth, and causing apoptosis. Its exact mechanism of action remains unclear. (NCI04)
Hexamethylene bisacetamide (HMBA) is a hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines. It is a cell differentiation inducer and a selective bromodomain inhibitor that can cross the blood-brain barrier. It has a CAS number of 3073-59-4, a molecular weight of 200.28, and a molecular formula of C10H20N2O2. It is also known as NSC 95580. The compound is for research use only and has not been approved for clinical use. |
| Molecular Formula |
C10H20N2O2
|
|---|---|
| Molecular Weight |
200.28
|
| Exact Mass |
200.152
|
| CAS # |
3073-59-4
|
| PubChem CID |
3616
|
| Appearance |
White to off-white solid powder
|
| Density |
0.974 g/cm3
|
| Boiling Point |
456.7ºC at 760 mmHg
|
| Melting Point |
128-129 °C(lit.)
|
| Flash Point |
193.2ºC
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
14
|
| Complexity |
161
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(NCCCCCCNC(C)=O)=O
|
| InChi Key |
BNQSTAOJRULKNX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H20N2O2/c1-9(13)11-7-5-3-4-6-8-12-10(2)14/h3-8H2,1-2H3,(H,11,13)(H,12,14)
|
| Chemical Name |
N-(6-acetamidohexyl)acetamide
|
| Synonyms |
HMBA; Hexamethylene bisacetamide; Diacetyldiaminohexane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~124.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9930 mL | 24.9650 mL | 49.9301 mL | |
| 5 mM | 0.9986 mL | 4.9930 mL | 9.9860 mL | |
| 10 mM | 0.4993 mL | 2.4965 mL | 4.9930 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05178069 | Recruiting | Drug:Placebo for Probiotic | Alcohol Use Disorder | University of Louisville | June 1, 2022 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
